Several studies have shown that the administration of SGLT2 inhibitors has proven efficacy in terms of reducing plasma levels of ALT, body weight [77], and blood pressure and improving glycated hemoglobin (HbA1c) [78], reducing risks of cardiovascular and renal diseases, all of which are factors that inhibit the progression to NASH [79]. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.